Supreme Pre-emption: Legislators, Journals, Former FDA Heads Unite vs. Wyeth
The plaintiff bar and the pharmaceutical industry have rallied their allies as they prepare for a hearing before the U.S. Supreme Court that could change the outcome of product liability litigation
You may also be interested in...
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
January’s proposed rule remains mostly unchanged, but the definition of “newly acquired information” is slightly broader now.
Court lets lower court ruling against Warner-Lambert stand but does not answer question regarding federal preemption in product liability.